- Home
- DSGN vs ATLO Comparison
DSGN vs ATLO Comparison
Compare DSGN & ATLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- ATLO
- Stock Information
- Founded
- DSGN 2017
- ATLO 1903
- Country
- DSGN United States
- ATLO United States
- Employees
- DSGN N/A
- ATLO N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- ATLO Major Banks
- Sector
- DSGN Health Care
- ATLO Finance
- Exchange
- DSGN Nasdaq
- ATLO Nasdaq
- Market Cap
- DSGN 264.4M
- ATLO 174.1M
- IPO Year
- DSGN 2021
- ATLO N/A
- Fundamental
- Price
- DSGN $4.67
- ATLO $18.09
- Analyst Decision
- DSGN Hold
- ATLO
- Analyst Count
- DSGN 3
- ATLO 0
- Target Price
- DSGN $7.00
- ATLO N/A
- AVG Volume (30 Days)
- DSGN 181.2K
- ATLO 14.3K
- Earning Date
- DSGN 08-05-2024
- ATLO 10-18-2024
- Dividend Yield
- DSGN N/A
- ATLO 5.58%
- EPS Growth
- DSGN N/A
- ATLO N/A
- EPS
- DSGN N/A
- ATLO 1.06
- Revenue
- DSGN N/A
- ATLO $51,275,000.00
- Revenue This Year
- DSGN N/A
- ATLO N/A
- Revenue Next Year
- DSGN N/A
- ATLO N/A
- P/E Ratio
- DSGN N/A
- ATLO $17.03
- Revenue Growth
- DSGN N/A
- ATLO N/A
- 52 Week Low
- DSGN $1.96
- ATLO $15.01
- 52 Week High
- DSGN $5.48
- ATLO $22.50
- Technical
- Relative Strength Index (RSI)
- DSGN 50.29
- ATLO 44.10
- Support Level
- DSGN $4.52
- ATLO $17.65
- Resistance Level
- DSGN $4.87
- ATLO $18.45
- Average True Range (ATR)
- DSGN 0.36
- ATLO 0.61
- MACD
- DSGN -0.04
- ATLO 0.05
- Stochastic Oscillator
- DSGN 19.80
- ATLO 34.04
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About ATLO Ames National Corporation
Ames National Corporation is a United States-based bank holding company. Through its subsidiaries, it provides checking, savings and time deposits, cash management services, merchant credit card processing, safe deposit boxes, wire transfers, direct deposit of payroll and social security checks, and automated/video teller machine access. Its loan portfolio comprises commercial, residential & agricultural real estate loans; agricultural & business operating loans & lines of credit; equipment loans; vehicle loans; personal loans; and mortgage loans. Its operations are conducted in central, north central, and south-central Iowa.